嘉必優(688089.SH):N-乙酰神經氨酸產品與已批准的新食品原料N-乙酰神經氨酸具有實質等同性
格隆匯8月1日丨嘉必優(688089.SH)公佈,公司近日從國家衞生健康委員會網站獲悉,公司全資子公司武漢中科光谷綠色生物技術有限公司自主研發並生產的N-乙酰神經氨酸產品(菌株號:CASOV-09)與已批准的新食品原料N-乙酰神經氨酸(原衞生計生委2017年第7號公吿,菌株號:SA-8)具有實質等同性。
此次新食品原料申報審查結果明確了公司子公司中科光谷生產的N-乙酰神經氨酸產品與已批准的新食品原料的實質等同關係。此次審查意見不會對公司現有客户及合作業務產生直接影響。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.